New Bloomberg article regarding Bionor Pharma ASA
Article revised
.2011
News
Tester nesevaksine mot HIV
Oslo 02.12.2011 - På World AIDS day 1. desember 2011 skriver forskning.no om den pågående kliniske studien ved Oslo Universitetssykehus, hvor Bionor Pharma’s HIV vaksinekandidat Vacc-4x testes ut på HIV positive pasienter ved vaksinering i nesen.
Read more about Tester nesevaksine mot HIVBionor Pharma develops universal influenza vaccine
Washington, 22.11.2011 - Bionor Pharma’s Universal Influenza Vaccine, Vacc-Flu, Targets Regions Shared by all Influenza A Strains; Reduces Serious Flu Symptoms by 25 Percent Over Standard Flu Vaccine in Animal Study.
Read more about Bionor Pharma develops universal influenza vaccineBionor Pharma ASA utvikler universell influensavaksine
Washington, 10.11.2011 - Bionor Pharma presenterer sin forebyggende influensavaksine Vacc-Flu på den viktigste årlige influensakongressen i USA (Arlington, Virginia).
Read more about Bionor Pharma ASA utvikler universell influensavaksineBionor Pharma presents on an Influenza congress in US
(Oslo, 31th October, 2011 - Bionor Pharma is invited to present its work on development on an Influenza vaccine on an influenza congress in USA
Read more about Bionor Pharma presents on an Influenza congress in USBionor Pharma presenterer på influensakongress i USA
Oslo, 31.10.2011 - Bionor Pharma invitert til å presentere sin influensasatsing på influensakongress i USA.
Read more about Bionor Pharma presenterer på influensakongress i USAVacc-4x presented at AIDS Vaccine 2011 in Bangkok
(BANGKOK, Sep 12, 2011) Bionor Pharma presented Vacc-4x on "Global HIV Vaccine Enterprise" press conference at AIDS Vaccine 2011 in Bangkok
Read more about Vacc-4x presented at AIDS Vaccine 2011 in BangkokVacc-4x presenteres på "Global HIV Vaccine Enterprise" i Bangkok
Bangkok, 12.09.2011 - Bionor Pharma er invitert til å presentere Vacc-4x på pressekonferansen til "Global HIV Vaccine Enterprise" ved AIDS Vaccine 2011 i Bangkok.
Read more about Vacc-4x presenteres på "Global HIV Vaccine Enterprise" i BangkokNew clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)
Oslo - 25.08.11 - Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug
Read more about New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)Ny klinisk studie, HIV Vacc-4x i kombinasjon med REVLIMID® (Lenalidomide)
Oslo - 25.08.2011 Bionor Pharma ASA vil studere effekten av Bionors terapeutiske HIV-vaksine Vacc-4x, i kombinasjon med REVLIMID® (Lenalidomide), hos pasienter med HIV.
Read more about Ny klinisk studie, HIV Vacc-4x i kombinasjon med REVLIMID® (Lenalidomide)Vacc-4x phase IIB study accepted as a poster at AIDS conference in Bangkok
Oslo, 01.08.2011 - An abstract of Bionor Pharma's Vacc-4x phase IIB study has been accepted as a poster at the AIDS Vaccine 2011 conference in Bangkok 12-15 September.
Read more about Vacc-4x phase IIB study accepted as a poster at AIDS conference in BangkokSuccessful therapeutic vaccination with Vacc-4x
Successful therapeutic vaccination of HIV patients with Vacc-4x, Bionor Pharma’s peptide-based therapeutic vaccine for HIV-1 infection
Read more about Successful therapeutic vaccination with Vacc-4xVacc-4x phase IIB study accepted as a poster at the IAS conference
Oslo, 21.06.2011 - An abstract of Bionor Pharma's Vacc-4x phase IIB study has been accepted as poster at the IAS conference in Rome 17-20 July 2011.
Read more about Vacc-4x phase IIB study accepted as a poster at the IAS conferenceNMA (SLV) approve testing of Vacc-4x using a nasal administration system
Oslo, 16.06.2011 - Oslo University Hospital has received approval to test Bionor Pharma's HIV-vaccine, Vacc-4x, using a nasal administration system
Read more about NMA (SLV) approve testing of Vacc-4x using a nasal administration systemExpert-reviews on universal influenza vaccine
Oslo, 25.05.2011 - Interview with CSO Maja Sommerfelt regarding universal flu vaccine
Read more about Expert-reviews on universal influenza vaccineBionor Pharma strengthens its IP-platform in the US
Oslo, 20.05.2011 - Bionor Pharma ASA has today received confirmation of submission of patent
applications in the US for its platform technologies.